New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells

Tyrosine kinase enzymes are among the primary molecular targets for the treatment of some human neoplasms, such as those in lung cancer and chronic myeloid leukemia. Mutations in the enzyme domain can cause resistance and new inhibitors capable of circumventing these mutations are highly desired. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Andressa, Moura, Stefany, Pimentel, Luiz, Neto, João, Dantas, Rafael, Silva-Jr, Floriano, Bastos, Monica, Boechat, Nubia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838532/
https://www.ncbi.nlm.nih.gov/pubmed/35164014
http://dx.doi.org/10.3390/molecules27030750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838532/
https://www.ncbi.nlm.nih.gov/pubmed/35164014
http://dx.doi.org/10.3390/molecules27030750

Ejemplares similares